COVID-19 (Novel Coronavirus): Please click here for FAQs: Impact of COVID-19 on Human Subjects Research – Who, How, Consent Form Posting, Legal Requirements

Who is responsible for registration and results reporting on

Compliance with regulations that pertain to is the responsibility of either the Principal Investigator (for PI initiated studies) or the sponsor.  This begins with complying with all BMC/BU Medical Campus HRPP Policies that pertain to clinical trials (section 6.6.9).  The BMC/BU Medical Campus Administrator of provides information, guidance and support in all aspects of with additional oversight by the BMC Research Compliance Officer and the Director of the Office of Human Research Affairs (OHRA).

For investigator-initiated clinical trials, the Principal Investigator is considered the Responsible Party (RP), and is the one who has to complete the registration.  For multi-center clinical trials, someone other than the local PI usually fulfills this responsibility (eg the sponsor). The Responsible Party who initially registers the clinical trial must maintain the information about the trial, including verifying all information in the record such as the overall study status, keeping all ‘anticipated’ study dates current, integrating relevant IRB amendments and recruitment information, and posting final results and documents, if required. Different types of information require updating within 15 or 30 days after a change and at a minimum the entire record needs to be reviewed and all information checked for accuracy/verified at least annually. The PI/RP can identify members of their research team who can also have access to the record and thereby assist in maintaining and making needed edits to the record.  Their names should be given to the PRS Administrator who can make them new users and give them access to their specific study/ies. However, only the RP can release the record for PRS review, and until the record is released and then reviewed the changes/edits cannot be published/made public on


How do you register a study on

Record registration on is a process that starts when the RP creates a new record.  This requires contacting the institutional PRS Administrator who will make the PI/Responsible Party a user.   The PRS Administrator then provides the user with a username and emails the user instructions on how to create a password.  The RP/user who is also the record owner then goes to and enters the Organization name, their username and password and creates a new record.  There are many tools and tips in to help the RP or delegated research team member create the registration record.  In addition, at the top of each section within  the protocol section there are links to ‘Definitions’ and ‘Help’ which provide guidance as to which options to select and how to complete each section.  You can always contact your PRS Administrator who can provide guidance and answer questions.

Once complete, reviewed, and approved by the PRS Administrator, the record is released for PRS review.  A staff member will then review the study record and focus on apparent validity, meaningful entries, logic and internal consistency, and formatting. The RP may be asked to clarify items or make corrections to the record before publication which can take a few days.  Ensuring that the record is consistent with the Protocol Review Criteria before releasing it will expedite publication on Once review staff accept it for publication, the record, including its NCT Number, will be available on within 2–5 business days.


How do you report results on

Reporting results on is an important and time-consuming process that should start months before the 10-month window after the actual primary completion date when results are expected.  There are many tools to assist this process on and the PRS Administrator can be very helpful during this process.


How to post a consent form on and comply with 45 CFR 46.116(h)?

 One of the revisions of the 2018 Common Rule that became effective on January 21, 2019 [45 CFR 46.116(h)] specifies that a consent form must be posted on a federal website for all clinical trials who  receive specific federal funding* and are either (a) approved by an IRB on or after January 21, 2019 or (b) approved earlier but transitioned to Revised Common Rule requirements earlier than 61 days after the last study visit. The requirement states that:

  • an unsigned copy of one IRB-approved consent form that has been used in enrolling participants in a clinical trial conducted or supported by a Common Rule department/agency*
  • must be posted on a publicly available federal website
  • after recruitment closes and no later than 60 days after the last study visit

Compliance is required for all studies that meet the Common Rule definition of a clinical trial,

“a research study in which one or more human subjects are prospectively assigned to one or more interventions … to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes”.  This includes social, behavioral and educational clinical trials.

The purpose of the consent form-posting requirement is to be more transparent about consent forms being used in clinical trials and to ultimately improve the quality of consent forms. It is important to know that even if a consent form changes during the clinical trial, only one IRB-approved version of the consent form needs to be posted.

Although in the future other federal websites might be identified, currently there are two federal websites that have been identified for posting the consent forms –

For BMC/BU Medical Campus researchers, the policy is to post the consent form on

*for a list of the 20 Common Rule Departments and Agencies visit

For questions or assistance please contact Karla Damus, Administrator, and MCSR Research Licensure,, 617 358 5337. legal requirements

“Responsible parties” (as defined in 42 CFR 11.10(a)) must comply with the applicable provisions of section 402(j) of the Public Health Service Act (PHS Act) and the applicable regulations in 42 CFR part 11. The statute and regulations set forth the requirements for responsible parties to submit registration and summary results information to the data bank for specified “applicable clinical trials” (ACTs) of drug products (including biological products) and device products.

ACTs are described in section 402(j)(1)(A) of the PHS Act and in 42 CFR 11.10(a). Any applicable clinical trial that (1) is initiated after September 27, 2007, or (2) was initiated on or before September 27, 2007, and was ongoing on December 26, 2007, must be registered with the data bank (see section 402(j)(2)(C) of the PHS Act and 42 CFR 11.22(a)). For ACTs that are required to be registered, 42 CFR 11.42 describes for which trials results information must be submitted (see 81 FR 65121 for summary table) and whether they must submit the results information specified in sections 402(j)(3)(C) and 402(j)(3)(I) of the PHS Act or the results information specified in 42 CFR 11.48.

42 CFR 11.66 describes the potential legal consequences for responsible parties if they do not comply with the requirements to submit registration and results information on applicable clinical trials. Such potential legal consequences include civil or criminal judicial actions, civil monetary penalty actions, and grant funding actions.

In 2019, potential fines for late FDAAA were $12,103/day.